Sorry, you need to enable JavaScript to visit this website.

Support & Resources | RYBREVANT® (amivantamab-vmjw) HCP

Videos for HCPs


Mechanism of Disease (MOD) Video

Learn what makes most EGFR exon 20 insertion mutations different.

Resources for HCPs


Amivantamab-vmjw (RYBREVANT®) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Flashcard

See the NCCN Guidelines® recommendations for
amivantamab-vmjw (RYBREVANT®).


RYBREVANT® Dosing and Administration Guide

Comprehensive dosing, dose modification, preparation, and administration details for RYBREVANT®.


Supportive Care Guide for RYBREVANT® Adverse Reactions

A helpful guide to address adverse reactions through proactive supportive care and reactive management.


Testing and Treatment for EGFR Exon 20 Insertion Mutation+ mNSCLC

An overview of the NCCN Guidelines® recommendations for the testing and treatment of mNSCLC with EGFR exon 20 insertion mutations.


Janssen CarePath

Janssen CarePath is your one source for access, affordability, and treatment support for your patients.


Reference Lab Fact Sheet

Biomarker testing guidelines and a list of liquid and tissue NGS test providers.


First-infusion Guide

A guide that focuses on how to manage IRRs during a patient’s first infusion of RYBREVANT® in first-line therapy.

Resources for Patients


RYBREVANT® Prospective Patient Brochure

Getting patients started on their journey with RYBREVANT®.


RYBREVANT® Patient Starter Kit Brochure

Helpful information for patients to manage their treatment.


RYBREVANT® Patient Starter Kit Advocacy Flashcard

Organizations in the mNSCLC community that provide support during treatment.


RYBREVANT® Patient Starter Kit Infusion Schedule Flashcard

An overview to help patients understand and prepare for their infusions during treatment.


RYBREVANT® Patient Starter Kit Treatment Journal

A tool to help patients stay organized, prepare, and reflect during their treatment with RYBREVANT®.


Janssen CarePath

Information on insurance coverage, out-of-pocket costs, and treatment support.


Janssen CarePath Savings Program for RYBREVANT®

Eligible commercially insured patients can save on their out-of-pocket medication costs for RYBREVANT®.

Resources for Access & Affordability


RYBREVANT® Medicare Payment Policy Flashcard

Important information regarding Medicare's payment policy for RYBREVANT®.


Coding & Billing Flashcard

An explanation for office staff about insurance codes and billing.


Specialty Distributor Flashcard

A flashcard on how to order RYBREVANT® for your patients.


Access and Reimbursement Guide

A helpful guide to navigating access for RYBREVANT®.


Sample Letter of Medical Necessity (LMN)

An editable LMN template to use either with an initial claim or when requesting reconsideration for a denied claim.


Sample Exception Letter

A template exception letter to use when requesting an exception for RYBREVANT®.

AMI, amivantamab; EGFR, epidermal growth factor receptor; HCP, healthcare professional; IRR, infusion-related reactions; KOL, key opinion leader; MOA, mechanism of action; mNSCLC, metastatic non-small cell lung cancer; NCCN, National Comprehensive Cancer Network; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer.

Patient Support


Lung Cancer Communities and Organizations

EGFR Resisters

The EGFR Resisters is a group of people living with and/or personally affected by EGFR-positive lung cancer.

Exon 20 Group

Patients and their families are welcome to join the Exon 20 Group. Membership is free of charge.

The GO2 Foundation for Lung Cancer

Founded by patients and survivors, GO2 Foundation for Lung Cancer transforms survivorship as the world’s leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.

Lung Cancer Foundation of America (LCFA)

LCFA’s mission is the improvement in survivorship of lung cancer patients through the funding of transformative science.


LUNGevity is the largest national lung cancer-focused nonprofit. They are committed to changing the outcomes for people with lung cancer through research, education, and support.

These groups and foundations are not affiliated with Janssen Biotech, Inc. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by Janssen Biotech, Inc., or any groups or foundations referenced herein.

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF)

The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, nonprofit organization. JJPAF gives eligible patients free prescription medicines donated by Johnson & Johnson companies. Patients may be eligible if they don’t have insurance.

Do you have patients who may need help? They can see if they are eligible and get an application at or call 800-652-6227 (Monday through Friday, 8:00 AM to 8:00 PM ET).




Dosing Guidelines

See the recommended dosing and administration for RYBREVANT®.

Learn more



Reduce the risk of progression
with RYBREVANT® + chemotherapy.

See Data


Register for Updates

Sign up to receive the latest news and information about RYBREVANT® by completing the registration form.